AstraZeneca (AZN) Stock Rating Reaffirmed by Shore Capital

Lloyd Doyle
December 7, 2017

The stock had previously closed at GBX 4,767 ($64.16).

Lapides Asset Management Llc decreased its stake in Verifone Systems Inc (PAY) by 3.79% based on its latest 2017Q2 regulatory filing with the SEC. The Signaturefd Llc holds 7,396 shares with $252,000 value, down from 19,359 last quarter. Citigroup Inc now has $203.32B valuation. The stock decreased 0.99% or $2.1 during the last trading session, reaching $209.97. About 2.29M shares traded. Public Storage (NYSE:PSA) has declined 14.14% since December 5, 2016 and is downtrending. It has underperformed by 48.63% the S&P500.

What Historical Figures Say About AstraZeneca PLC (NYSE: AZN)? The company has market cap of 59.53 billion GBP. It has a 15.42 P/E ratio. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Among 12 analysts covering Telus Corporation (NYSE:TU), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 52% are positive. Jefferies Group LLC lowered their price target on AstraZeneca plc from GBX 5,400 ($69.36) to GBX 4,800 ($61.66) and set a buy rating for the company in a research report on Monday, January 30th. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. UBS maintained the stock with "Buy" rating in Wednesday, December 7 report. The firm has "Market Perform" rating given on Friday, September 4 by BMO Capital Markets. AstraZeneca PLC was covered by a number of analysts recently, 3 rated the stock as Buy, 1 rated Outperform, 1 rated Hold, 0 gave an Underperform and 0 rated sell. Credit Suisse maintained the stock with "Neutral" rating in Monday, March 21 report. The rating was upgraded by Credit Suisse to "Buy" on Monday, October 16. The stock has "Hold" rating by Shore Capital on Tuesday, May 23.


TRADEMARK VIOLATION NOTICE: This article was first published by StockNewsTimes and is the property of of StockNewsTimes. Comparatively, AstraZeneca PLC posted earnings of $0 per share in the same quarter previous year. The company reported $1.12 EPS for the quarter, beating the Zacks' consensus estimate of $0.57 by $0.55. The stock increased 0.92% or $0.16 during the last trading session, reaching $17.5. About 7.96 million shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since December 5, 2016 and is uptrending. Pnc Fincl Svcs Gru Inc invested 0% in VeriFone Systems, Inc. It also reduced Cvs Health Corp (NYSE:CVS) stake by 44,431 shares and now owns 1.54M shares. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) was raised too.

Among 31 analysts covering Verifone Systems Inc. Therefore 13% are positive.

On Wall Street, the benchmark S&P 500.SPX set a record intraday high, but then pulled back and finished lower, while the Dow industrials still managed a record high close. Analysts believe that we could see stock price minimum in the $24.92 range (lowest target price), allowing for another -24.14% drop from its current position. Verifone Systems Inc. had 73 analyst reports since August 5, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with "Sector Perform" rating and $20 target in Friday, June 9 report. The company was maintained on Wednesday, October 11 by KeyBanc Capital Markets. More interesting news about AstraZeneca PLC (NYSE:AZN) was released by: Investorplace.com and their article: "AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment" with publication date: July 27, 2017. The company was maintained on Monday, October 16 by Robert W. Baird. The company was downgraded on Tuesday, July 26 by Macquarie Research. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. The rating was maintained by BMO Capital Markets with "Buy" on Thursday, September 14. On Friday, November 25 the stock rating was upgraded by Liberum Capital to "Buy". The firm earned "Equal-Weight" rating on Friday, September 2 by Barclays Capital.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER